Tuesday, 3 March 2015

Epstein-Barr Viral Infections - Pipeline Review, H1 2015

Epstein-Barr Viral Infections - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Epstein-Barr Viral Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epstein-Barr Viral Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epstein-Barr Viral Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Scope

- The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epstein-Barr Viral Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epstein-Barr Viral Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epstein-Barr Viral Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Cell Medica Limited Epiphany Biosciences, Inc. Theravectys S.A. ViroStatics, srl



To access full report with TOC, please visit Epstein-Barr Viral Infections - Pipeline Review, H1 2015

 About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research



Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015

Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Chemotherapy Induced Nausea and Vomiting’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Nausea and Vomiting, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Nausea and Vomiting and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from The proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Nausea and Vomiting and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chemotherapy Induced Nausea and Vomiting products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Nausea and Vomiting pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

Acacia Pharma Ltd. Aphios Corporation Genovate Biotechnology Co., LTD. Helsinn Holding S.A. Heron Therapeutics, Inc. INSYS Therapeutics, Inc. Kyowa Hakko Kirin Co., Ltd. Merck & Co., Inc. RedHill Biopharma Ltd. Shin Nippon Biomedical Laboratories, Ltd. Sparsha Pharma International Pvt. Ltd. Suda Ltd Teikoku Pharma USA, Inc. Tesaro, Inc.



To access full report with TOC, please visit Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2015

 About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research

Vasculitis - Pipeline Review, H1 2015

Vasculitis - Pipeline Review, H1 2015 is a new market research publication announced by Reportstack. This report provides an overview of the Vasculitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from team's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team members. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Companies Mentioned

AnGes MG, Inc. Anthera Pharmaceuticals‚ Inc. Aprogen, Inc. ChemoCentryx, Inc. Clearside BioMedical, Inc. Epirus Biopharmaceuticals, Inc. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc Hemostemix Ltd Hospira, Inc. K-Stemcell Co., Ltd. Panacea Biotec Limited Pluristem Therapeutics Inc. Sandoz Inc. XOMA Corporation



To access full report with TOC, please visit Vasculitis - Pipeline Review, H1 2015

 About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.

Contact:

Debora White
Manager - Marketing
debora@reportstack.com
Ph: +1-888-789-6604
Reportstack Market Research